BioStock: BioInvent prepares for a data-rich 2025

BioInvent wrapped up 2024 with notable progress across its six clinical programs focusing on the developing antibodies for cancer therapy. With two phase II and four phase I trials ongoing BioInvent is heading for a milestone-rich 2025 with numerous data readouts expected.

Read the article at biostock.se:

https://www.biostock.se/en/2025/03/bioinvent-prepares-for-a-data-rich-2025/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/